We’re one step closer to open-source collaboration in the life sciences – and could come a hell of a lot closer to completely revolutionizing cancer treatment – thanks to a promising new alliance formed by the top brass in biopharma.
Meant to accelerate the potential of immunotherapy in treating cancer, The National Immunotherapy Coalition has just been launched by leaders from Amgen, Celgene, GlaxoSmithKline, Merck, and NantWorks – along with Independence Blue Cross and many others. Here’s why: